Evidence map›Paper›PMID 31700155›Full record

ArticleOncogene2020

The exosome-mediated autocrine and paracrine actions of plasma gelsolin in ovarian cancer chemoresistance.

Meshach Asare-Werehene, Kiran Nakka, Arkadiy Reunov, Chen-Tzu Chiu, Wei-Ting Lee, Mohammad R Abedini, Pei-Wen Wang, Dar-Bin Shieh, F Jeffrey Dilworth, Euridice Carmona and 4 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncogene, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers.

0numbers the graph read from it
0cells of the map it votes in
97citing papers in PubMed
4.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

97 citing papers in PubMed, 132 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review

37 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 3 countries.

Meshach Asare-WereheneDepartments of Obstetrics & Gynecology and Cellular & Molecular Medicine, University of Ottawa, Ottawa, ON, Canada.
Kiran NakkaChronic Disease Program and Regenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, ON, K1H 8L6, Canada.ORCID http://orcid.org/0000-0002-8418-9343
Arkadiy ReunovDepartment of Biology, St. Francis Xavier University, 2320 Notre Dame Avenue, Antigonish, NS, B2G 2W5, Canada.
Chen-Tzu ChiuInstitute of Basic Medical Science, Institute of Oral Medicine and Department of Stomatology, National Cheng Kung University Hospital, National Cheng Kung University, Tainan, 704, Taiwan.
Wei-Ting LeeInstitute of Basic Medical Science, Institute of Oral Medicine and Department of Stomatology, National Cheng Kung University Hospital, National Cheng Kung University, Tainan, 704, Taiwan.
Mohammad R AbediniChronic Disease Program and Regenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, ON, K1H 8L6, Canada.
Pei-Wen WangInstitute of Basic Medical Science, Institute of Oral Medicine and Department of Stomatology, National Cheng Kung University Hospital, National Cheng Kung University, Tainan, 704, Taiwan.
Dar-Bin ShiehInstitute of Basic Medical Science, Institute of Oral Medicine and Department of Stomatology, National Cheng Kung University Hospital, National Cheng Kung University, Tainan, 704, Taiwan.
F Jeffrey DilworthChronic Disease Program and Regenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, ON, K1H 8L6, Canada.ORCID http://orcid.org/0000-0002-6265-8102
Euridice CarmonaCentre de recherche du CHUM et Institut du cancer de Montréal, Montréal, QC, H2X 0A9, Canada.
Tien LeDepartments of Obstetrics & Gynecology and Cellular & Molecular Medicine, University of Ottawa, Ottawa, ON, Canada.
Anne-Marie Mes-MassonCentre de recherche du CHUM et Institut du cancer de Montréal, Montréal, QC, H2X 0A9, Canada.
Dylan BurgerChronic Disease Program and Regenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, ON, K1H 8L6, Canada.
Benjamin K TsangDepartments of Obstetrics & Gynecology and Cellular & Molecular Medicine, University of Ottawa, Ottawa, ON, Canada. btsang@ohri.ca.
University of Ottawa · CANational Cheng Kung University Hospital · TWCentre Hospitalier de l’Université de Montréal · CAOttawa Hospital · CASt. Francis Xavier University · CA

Funding

Gouvernement du Canada | Canadian Institutes of Health Research (Instituts de Recherche en Santé du Canada) MOP-15691
6 · The paper itself

Abstract

Ovarian cancer (OVCA) is the most lethal gynecological cancer, due predominantly to late presentation, high recurrence rate and common chemoresistance development. The expression of the actin-associated protein cytosolic gelsolin (GSN) regulates the gynecological cancer cell fate resulting in dysregulation in chemosensitivity. In this study, we report that elevated expression of plasma gelsolin (pGSN), a secreted isoform of GSN and expressed from the same GSN gene, correlates with poorer overall survival and relapse-free survival in patients with OVCA. In addition, it is highly expressed and secreted in chemoresistant OVCA cells than its chemosensitive counterparts. pGSN, secreted and transported via exosomes (Ex-pGSN), upregulates HIF1α-mediated pGSN expression in chemoresistant OVCA cells in an autocrine manner as well as confers cisplatin resistance in otherwise chemosensitive OVCA cells. These findings support our hypothesis that exosomal pGSN promotes OVCA cell survival through both autocrine and paracrine mechanisms that transform chemosensitive cells to resistant counterparts. Specifically, pGSN transported via exosomes is a determinant of chemoresistance in OVCA.

Indexed as

Drug Resistance, NeoplasmApoptosisAutocrine CommunicationExosomesFemaleGelsolinGene Expression Regulation, NeoplasticHumansHypoxia-Inducible Factor 1, alpha SubunitIntegrin alpha5beta1Ovarian NeoplasmsParacrine CommunicationProto-Oncogene Proteins c-aktSignal TransductionUp-RegulationGelsolinHIF1A protein, humanHypoxia-Inducible Factor 1, alpha SubunitIntegrin alpha5beta1Proto-Oncogene Proteins c-akt

Identifiers

PMID31700155
PMCPMC7018662
OpenAlexW2982746393

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.